Real-World Performance of High-Flux Dialyzers in Patients With Hypoalbuminemia.
Journal
ASAIO journal (American Society for Artificial Internal Organs : 1992)
ISSN: 1538-943X
Titre abrégé: ASAIO J
Pays: United States
ID NLM: 9204109
Informations de publication
Date de publication:
01 01 2022
01 01 2022
Historique:
pubmed:
27
6
2021
medline:
2
2
2022
entrez:
26
6
2021
Statut:
ppublish
Résumé
There is little research on factors that influence the choice of dialyzer in patients undergoing hemodialysis. In patients at risk for poorer outcomes, including those with hypoalbuminemia, understanding how this choice impacts clinical parameters could inform patient management. The objective of this real-world analysis was to evaluate the use and performance of four single-use (i.e., nonreuse [NR]), high-flux Optiflux dialyzers with varying surface areas (F160NR [1.5 m2], F180NR [1.7 m2], F200NR [1.9 m2], and F250NR [2.5 m2]) in patients (N = 271) with baseline hypoalbuminemia (≤3.5 g/dl) receiving hemodialysis at a medium-sized dialysis organization. Thrice weekly, in-center dialysis was delivered for 6 months without adjustments to the hemodialysis prescription. Larger dialyzers were more frequently used in men, patients with higher body mass indices, and those with diabetes. Increases in serum albumin from baseline (month 1) to month 6 (p < 0.05) were observed with all dialyzer sizes. A mean increase in hemoglobin of 0.31 g/dl was also observed (p < 0.001). Among patients exhibiting increased serum albumin levels (n = 177), reductions in the neutrophil-to-lymphocyte ratio, a marker of inflammation, were observed (mean: 0.90; p < 0.001). These results support the use of high-flux dialyzers in patients with hypoalbuminemia.
Identifiants
pubmed: 34172639
doi: 10.1097/MAT.0000000000001511
pii: 00002480-202201000-00015
pmc: PMC8700293
doi:
Substances chimiques
Hemoglobins
0
Membranes, Artificial
0
Serum Albumin
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
96-102Informations de copyright
Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the ASAIO.
Références
United States Renal Data System: 2019 USRDS annual data report: Epidemiology of kidney disease in the United States. Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2019.
Ward RA: Do clinical outcomes in chronic hemodialysis depend on the choice of a dialyzer? Semin Dial. 24: 65–71, 2011.
Chelamcharla M, Leypoldt JK, Cheung AK: Dialyzer membranes as determinants of the adequacy of dialysis. Semin Nephrol. 25: 81–89, 2005.
Chowdhury NS, Islam FMM, Zafreen F, et al.: Effect of surface area of dialyzer membrane on the adequacy of haemodialysis. J Armed Forces Med Coll Bangladesh. 7: 9–11, 2012.
Mandolfo S, Malberti F, Imbasciati E, Cogliati P, Gauly A: Impact of blood and dialysate flow and surface on performance of new polysulfone hemodialysis dialyzers. Int J Artif Organs. 26: 113–120, 2003.
Fresenius Medical Care North America: Instructions for use: Optiflux ® , Waltham, MA, Fresenius Medical Care, 2016.
Hanna RM, Ghobry L, Wassef O, Rhee CM, Kalantar-Zadeh K: A practical approach to nutrition, protein-energy wasting, sarcopenia, and cachexia in patients with chronic kidney disease. Blood Purif. 49: 202–211, 2020.
Ward RA, Beck W, Bernardo AA, Alves FC, Stenvinkel P, Lindholm B: Hypoalbuminemia: A price worth paying for improved dialytic removal of middle-molecular-weight uremic toxins? Nephrol Dial Transplant. 34: 901–907, 2019.
Kalantar-Zadeh K, Ikizler TA, Block G, Avram MM, Kopple JD: Malnutrition-inflammation complex syndrome in dialysis patients: Causes and consequences. Am J Kidney Dis. 42: 864–881, 2003.
Herselman M, Esau N, Kruger JM, Labadarios D, Moosa MR: Relationship between serum protein and mortality in adults on long-term hemodialysis: Exhaustive review and meta-analysis. Nutrition. 26: 10–32, 2010.
Gotta V, Tancev G, Marsenic O, Vogt JE, Pfister M: Identifying key predictors of mortality in young patients on chronic haemodialysis-a machine learning approach. Nephrol Dial Transplant, 36: 519–528, 2020.
Karaboyas A, Morgenstern H, Li Y, et al.: Estimating the fraction of first-year hemodialysis deaths attributable to potentially modifiable risk factors: Results from the DOPPS. Clin Epidemiol. 12: 51–60, 2020.
Kalantar-Zadeh K, Kilpatrick RD, Kuwae N, et al.: Revisiting mortality predictability of serum albumin in the dialysis population: Time dependency, longitudinal changes and population-attributable fraction. Nephrol Dial Transplant. 20: 1880–1888, 2005.
Hakim RM: Assessing the adequacy of dialysis. Kidney Int. 37: 822–832, 1990.
US-DOPPS (Dialysis Outcomes and Practice Patterns Study) Practice Monitor: Achieved dialysis session length, continuous (minutes). 2020. Available at: https://www.dopps.org/DPM/Files/qdialysisduration_overallTAB.htm . Accessed December 22, 2020.
US-DOPPS (Dialysis Outcomes and Practice Patterns Study) Practice Monitor: Vascular access in use. 2020. Available at: https://www.dopps.org/DPM/Files/vType_c_overallTAB.htm . Accessed December 22, 2020.
US-DOPPS (Dialysis Outcomes and Practice Patterns Study) Practice Monitor: Single-pool Kt/V, continuous (spKtV). 2020. Available at: https://www.dopps.org/DPM/Files/singlepoolktv_overallTAB.htm . Accessed December 22, 2020.
National Kidney Foundation: KDOQI Clinical Practice Guideline for Hemodialysis Adequacy: 2015 update. Am J Kidney Dis. 66: 884–930, 2015.
Chan CT, Blankestijn PJ, Dember LM, et al.; Conference Participants: Dialysis initiation, modality choice, access, and prescription: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 96: 37–47, 2019.
Ficociello LH, Li Y, Mullon C, Costanzo M, Kossmann RJ: Retrospective analysis of serum albumin and other biomarkers in chronic hemodialysis patients dialyzed with the Optiflux F180NR dialyzer. Poster presented at: American Society of Nephrology Kidney Week 2019, November 5–10, 2019, Washington, DC. PO430.
Zhou M, Ficociello LH, Costanzo M, Mullon C, Kossmann RJ: Evaluation of biomarkers in chronic hemodialysis (HD) patients dialyzed with Optiflux high-flux dialyzers. ePoster presented at: American Society of Nephrology Kidney Week 2020, October 19-25, 2020. PO1168.
US-DOPPS (Dialysis Outcomes and Practice Patterns Study) Practice Monitor: Serum albumin (3 month average), categories. 2020. Available at: https://www.dopps.org/DPM/Files/meanalbumingdl_c_overallTAB.htm . Accessed December 22, 2020.
Nakazato Y, Kurane R, Hirose S, Watanabe A, Shimoyama H: Aging and death-associated changes in serum albumin variability over the course of chronic hemodialysis treatment. PLoS One. 12: e0185216, 2017.
Dalrymple LS, Johansen KL, Chertow GM, et al.: Longitudinal measures of serum albumin and prealbumin concentrations in incident dialysis patients: The comprehensive dialysis study. J Ren Nutr. 23: 91–97, 2013.
Goldwasser P, Kaldas AI, Barth RH: Rise in serum albumin and creatinine in the first half year on hemodialysis. Kidney Int. 56: 2260–2268, 1999.
Kotanko P, Thijssen S, Usvyat L, et al.: Temporal evolution of clinical parameters before death in dialysis patients: A new concept. Blood Purif. 27: 38–47, 2009.
Leavey SF, Strawderman RL, Young EW, et al.: Cross-sectional and longitudinal predictors of serum albumin in hemodialysis patients. Kidney Int. 58: 2119–2128, 2000.
Usvyat LA, Barth C, Bayh I, et al.: Interdialytic weight gain, systolic blood pressure, serum albumin, and C-reactive protein levels change in chronic dialysis patients prior to death. Kidney Int. 84: 149–157, 2013.
Hulko M, Haug U, Gauss J, Boschetti-de-Fierro A, Beck W, Krause B: Requirements and pitfalls of dialyzer sieving coefficients comparisons. Artif Organs. 42: 1164–1173, 2018.
Balboul Y, Gurshumov A, Azar A, Stav K, Efrati S, Beberashvili I: Biological basis of lymphocyte ratios for survival prediction in hemodialysis patients: A longitudinal study. Int Urol Nephrol. 52: 1345–1356, 2020.
Catabay C, Obi Y, Streja E, et al.: Lymphocyte cell ratios and mortality among incident hemodialysis patients. Am J Nephrol. 46: 408–416, 2017.
Diaz-Martinez J, Campa A, Delgado-Enciso I, et al.: The relationship of blood neutrophil-to-lymphocyte ratio with nutrition markers and health outcomes in hemodialysis patients. Int Urol Nephrol. 51: 1239–1247, 2019.
Okyay GU, Inal S, Oneç K, et al.: Neutrophil to lymphocyte ratio in evaluation of inflammation in patients with chronic kidney disease. Ren Fail. 35: 29–36, 2013.
Turkmen K, Guney I, Yerlikaya FH, Tonbul HZ: The relationship between neutrophil-to-lymphocyte ratio and inflammation in end-stage renal disease patients. Ren Fail. 34: 155–159, 2012.
Nowak KL, Chonchol M: Does inflammation affect outcomes in dialysis patients? Semin Dial. 31: 388–397, 2018.
Golubovic S, Knezevic V, Azasevac T, Bozic D, Celic D, Mitic I: Relationship between neutrophil-to-lymphocyte ration and platelet-to-lymphocyte ratio with erythropoietin resistance in hemodialysis patients. KI Reports. 5(suppl 3): S105, 2020.
de Francisco ALM, Stenvinkel P, Vaulont S: Inflammation and its impact on anaemia in chronic kidney disease: From haemoglobin variability to hyporesponsiveness. NDT Plus. 2(suppl 1): i18–i26, 2009.
Singh AK, Coyne DW, Shapiro W, Rizkala AR; DRIVE Study Group: Predictors of the response to treatment in anemic hemodialysis patients with high serum ferritin and low transferrin saturation. Kidney Int. 71: 1163–1171, 2007.
Rhee EP, Guallar E, Hwang S, et al.: Prevalence and persistence of uremic symptoms in incident dialysis patients. Kidney360. 1: 86–92, 2020.
Pupim LB, Himmelfarb J, McMonagle E, Shyr Y, Ikizler TA: Influence of initiation of maintenance hemodialysis on biomarkers of inflammation and oxidative stress. Kidney Int. 65: 2371–2379, 2004.
Borges Bonan N, Schepers E, Pecoits-Filho R, et al.: Contribution of the uremic milieu to an increased pro-inflammatory monocytic phenotype in chronic kidney disease. Sci Rep. 9: 10236, 2019.
Deppisch RM, Beck W, Goehl H, Ritz E: Complement components as uremic toxins and their potential role as mediators of microinflammation. Kidney Int Suppl. 78: S271–S277, 2001.
Yamamoto S, Kazama JJ, Wakamatsu T, et al.: Removal of uremic toxins by renal replacement therapies: A review of current progress and future perspectives. Renal Replacement Therapy. 2: 43, 2016.
Guinsburg AM, Usvyat LA, Etter M, et al.; Monitoring Dialysis Outcomes (MONDO) consortium: Seasonal variations in mortality and clinical indicators in international hemodialysis populations from the MONDO registry. BMC Nephrol. 16: 139, 2015.
Usvyat LA, Carter M, Thijssen S, et al.: Seasonal variations in mortality, clinical, and laboratory parameters in hemodialysis patients: A 5-year cohort study. Clin J Am Soc Nephrol. 7: 108–115, 2012.